EMA Withdrawn: Lusduna (insulin glargine) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA withdrew Lusduna (insulin glargine) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Lusduna (insulin glargine)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus. MAH: Merck Sharp & Dohme B.V.. Decision date: 29/10/2018